logo
That cucumber recall? You might want to check your fridge

That cucumber recall? You might want to check your fridge

USA Todaya day ago
Salmonella infects 1.35 million people every year. One expert said recalls are the last line of defense.
Does it feel like there have been lots of cucumber recalls lately?
You are not wrong. The Food and Drug Administration has classified 137 potential salmonella recall reports for food products containing cucumbers in 2025, more than in any other year with available data. The Centers for Disease Control and Prevention has linked cucumbers to a current salmonella outbreak.
Salmonella bacteria are a major cause of foodborne illness, infecting 1.35 million people and killing 420 people each year.
Since 2012, the Food and Drug Administration has classified over 3,200 salmonella food reports, according to federal data. On average, a salmonella recall lasts nearly a year, a USA TODAY review of the FDA data found. Currently, there are 217 salmonella recall reports ongoing.
You can explore the products here:
The FDA has the authority to mandate a recall, but about 99% are voluntarily issued by the companies that make the products.
After a recall is initiated, the agency classifies the health hazard presented by the product from Class I (a reasonable probability that the product will cause serious adverse health consequences or death) to Class III (the product is not likely to cause adverse health consequences).
About 44% of food recall reports have been classified as Class I. On the other hand, 80% of salmonella food reports are classified as Class I.
Most people get infected with salmonella by eating contaminated food like raw or undercooked meat, poultry, eggs, raw or unpasteurized milk and other dairy products, and produce. According to the CDC, 1 in 25 packages of chicken in the grocery store is contaminated with salmonella.
Department of Human and Health Services Secretary Robert Kennedy Jr. is among the many promoting raw milk, but experts caution against it.
'We have people whose families have had children and parents and others sickened after drinking raw milk,' said Sandra Eskin, CEO at the nonprofit Stop Foodborne Illness. 'It has salmonella in it, it can have E. coli, and it can have any number of pathogens. That's why they invented pasteurization.'
Warmer weather can also create ideal conditions for the bacteria to grow, so it's recommended to refrigerate perishable foods.
Other sources of salmonella include contaminated water and the handling of animals.
Symptoms start within six hours to six days from the time of exposure and include fever, diarrhea, nausea, vomiting and stomach pain. Most people recover within 4 to 7 days without treatment, but some cases lead to hospitalization and death.
Since the start of President Donald Trump's second term, there have been severe cuts and the federal health services workforce is expected to drop from 82,000 to 62,000, USA TODAY previously reported.
Trump argued the cuts are a way to save taxpayers' money, but experts say allocating resources towards food safety is critical.
An FDA spokesperson told USA TODAY in an email statement that the agency prioritizes food safety and is committed to working with all stakeholders.
'The layoffs relate to administrative staff positions in the FDA. There has been no impact to operational investigators conducting food safety inspections,' the FDA spokesperson said.
Over a decade ago, when annual salmonella numbers were estimated to be lower, the U.S. Department of Agriculture estimated that foodborne illness cost the country $3.7 billion per year, most of which was attributed to premature deaths.
Eskin, who previously worked at the U.S. Department of Agriculture overseeing food safety and inspections, said recalls are essential for public health.
'A recall is the last line of defense that you and I have to prevent getting sick,' Eskin said, 'if we're going to a restaurant, or more importantly, going to the grocery store.'
Dr. Susan Kansagra, chief medical officer at the Association of State and Territorial Health Officials, said in an email statement that federal funds support a wide range of state-level activities related to foodborne illness, like laboratory testing, case reporting, and guiding providers and the public on prevention and treatment.
'Loss of funding and staffing decreases our national capacity to do these activities and therefore quickly detect and respond to foodborne illness,' Kansagra said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ACHV: Achieve's Busy Day
ACHV: Achieve's Busy Day

Yahoo

time9 hours ago

  • Yahoo

ACHV: Achieve's Busy Day

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.

Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval
Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval

Forbes

time11 hours ago

  • Forbes

Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval

There are multiple smoking cessation products on the market. But there hasn't been a new approval of ... More a pharmacotherapy without nicotine in nearly 20 years. This could change soon, as cytisinicline was submitted to the FDA for approval on June 26, 2025. More than two-thirds of American smokers say they want to quit. However, besides nicotine replacement therapies, there are at present only two smoking cessation drugs without nicotine that are authorized for marketing by the Food and Drug Administration. This could change soon, as the pharmaceutical firm Achieve Life Sciences submitted to the FDA a new drug application last week for its prescription medicine, cytisinicline, also known as cytisine. The agency will review the medication's efficacy, safety, and tolerability profile based on evidence from two large, placebo-controlled Phase 3 clinical trials. The substance is a naturally occurring plant-based alkaloid that selectively binds to nicotinic receptors in the brain. In turn, this can help alleviate nicotine cravings and reduce withdrawal symptoms, among smokers of combustible cigarettes as well as e-cigarettes (vaping). Cytisinicline has been used as a smoking cessation product for decades in some Central and Eastern European countries. It was approved by the British Medicines and Healthcare products Regulatory Agency in March 2019, though only available commercially in the United Kingdom since January 2024. Cytisinicline hasn't yet been approved by the European Medicines Agency. The Journal of the American Medical Association Internal Medicine published results from one of two Phase 3 trials evaluating cytisinicline for smoking cessation. The authors' conclusions reaffirmed cytisinicline's efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction in nicotine cravings and extended cessation benefits through 24 weeks. Additionally, a study published in 2024 suggested cytisinicline could be effective for e-cigarette cessation. Owing to its mechanism of action as a way to reduce nicotine dependence, it's possible that cytisinicline could be beneficial for individuals using nicotine pouches who wish to stop, though this hasn't yet been examined specifically. Based on a technology assessment of the benefits and costs of cytisinicline, the British cost-effectiveness watchdog, the National Institute for Health and Care Excellence, recommended earlier this year adding the drug to the National Health Service as a treatment option for smoking cessation. And this week, the American Institute for Clinical and Economic Review announced it is conducting an evidence review to assess the clinical effectiveness of cytisinicline together with behavior support. The evaluation will include comparisons with other existing smoking cessation products. Smoking is the leading cause of preventable death in the U.S. Cigarette smoking is responsible for more than 480,000 deaths annually in the U.S. The major causes of death associated with smoking include cardiovascular diseases such as strokes and heart attacks; cancers, among which lung, pancreatic, esophageal, bladder, colorectal and renal; and pulmonary conditions such as chronic obstructive lung disease, pneumonia and bronchitis. Last October, the FDA and the National Institutes of Health convened a public meeting to address the urgency for developing novel smoking cessation products to assist individuals of all ages, including underserved and vulnerable populations, to stop smoking. There is unmet need in this space, reflected in the fact that of the 15 million who tried to quit smoking in 2022, five in six failed, according to STAT News. Experts cite a lack of sufficiently effective smoking cessation drugs. Should cytisinicline become available in the U.S. it could represent an important option for those who wish to quit their nicotine habit. At the same time, it will continue to be critical for healthcare providers and public health authorities to raise awareness around the importance of smoking cessation and prevention, provide behavior support (counseling) and offer treatment alternatives people can use to quit. The U.S. has made real progress since the 1960s in reducing cigarette smoking, mainly through effective public health campaigns. Yet there's still a lot more work to do as roughly 29 million adults smoke combustible cigarettes and approximately 17 million use e-cigarettes. But under the Trump administration the Department of Health and Human Services has cut funding for smoking cessation and prevention programs, as well as eliminated the Centers for Disease Control and Prevention's Office on Smoking and Health. While the CDC says it will continue to provide resources for those who wish to quit smoking while conducting ongoing surveillance, experts warn that cuts in services could limit access, which could then result in a resurgence in smoking rates.

Major Tourist Destinations Have a Hidden Transportation Hazard That Leaves Travelers and Locals Vulnerable
Major Tourist Destinations Have a Hidden Transportation Hazard That Leaves Travelers and Locals Vulnerable

Travel + Leisure

time17 hours ago

  • Travel + Leisure

Major Tourist Destinations Have a Hidden Transportation Hazard That Leaves Travelers and Locals Vulnerable

The newest travel hazard in cities might be something you aren't expecting at all. Electric scooters and e-bikes are ubiquitous throughout many cities in the world, and they aren't inherently dangerous. But the sheer number of them, combined with the potential for serious accidents, makes them a real and serious travel hazard for visitors. A study from 2024 by researchers at UC San Francisco have found that injuries from e-bikes have doubled every year from 2017 to 2022, and injuries from scooters have risen by 45 percent each year. 'This increase in accidents not only introduced a demographic shift, but also underscores an urgent need for added safety measures,' co-lead author Adrian Fernandez, a chief resident with the UCSF Department of Urology, said in a statement on the UCSF website. 'There are undeniable health and environmental benefits to micromobility vehicle use, but structural changes must be taken to promote safe riding.' In response, many major tourist destinations, including New York, Madrid, and Paris, have taken steps to ban or severely limit e-scooters, while others are close to going scooter-free. Often, e-bike and e-scooters behave around pedestrians in ways that put both riders and walkers at risk of injury. Though serious injuries are rare, they do happen. In 2024, a woman was severely injured in West Hollywood when she was hit by a motorized scooter, suffering a fractured skull and brain swelling that required hospitalization. An American man in Sydney nearly died after being hit by an e-bike that was riding in an area it was not permitted. He needed emergency brain surgery and spent weeks in a coma. And most run-ins between people and micromobility devices go unreported. Many more people have close calls or are clipped by speeding scooters, and these are experiences that can make people nervous in cities, which affects tourists. And tourists can also be responsible for the close calls, who rent e-bikes and scooters to joy ride around unfamiliar cities, leading to potential accidents. Riders of e-devices might feel unsafe riding on main streets alongside cars, but then become a hazard to pedestrians on sidewalks. Designated scoots lanes can help, but are not always available. 'As micromobility vehicles become more embedded in our daily lives, understanding and addressing the safety challenges they pose is critical,' corresponding author Benjamin N. Breyer, MD, MAS, the Taube Family Distinguished Professor and chair of the UCSF Department of Urology, said on the UCSF website. 'By doing so, we can harness the full potential of micromobility to create more sustainable, healthy and safe urban environments.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store